Syrios Ioannis

Syrios Ioannis Internist Oncologist

Director, 2nd Medical Oncology Department

Education & Academic Qualifications

  • Medical License Medical School, University of Athens, Greece 2003
  • Specialty in Medical Oncology 2013, Greece
  • Fellowship in Gynecological Cancer 2014, The Royal Marsden NHS Foundation Trust. 2013, London, UK
  • PhD Diploma Medical School, University of Athens, Greece 2012
  • MSc on Management of health care units Hellenic Open University 2016
  • ESMO Examination Certificate European Society of Medical Oncology 2012
  • Diploma of the Hellenic Boards of Oncology Hellenic Society of Medical Oncology 2012

Doctoral thesis

• ¨DNA ploidy and other factors affecting overall survival in patients with advanced gastric adenocarcinoma¨ Medical School, University of Athens, Greece 05.2007- 06.2012

Fellowship in Societies, Membership in Journal Editorial Committees

• ENGOT-EED member for clinical studies phase I-II (European Network for Gynaecological Oncological Trial group)

• Member of the European experts consensus panel for gynaecological oncology

• Ambassador of Greece and member of the KELIM working group

• Co-founder member of the management committee of COST Action: European network for Gynaecological Rare Cancer research: From Concept to Cure – GYNOCARE

• Member ESMO

• Ex-Member of General Medical Council with a Specialist registration (UK)

• Member of the Hellenic Society of Medical Oncology (HESMO)

• Member of the Hellenic Cooperative Oncology Group (HeCOG) and of the Hellenic Oncology Research Group (HORG)

• Ex Vice-President of Fertility Preservation in Cancer Patients Group (GONEAS)

• Member of the scientific board at MITERA Hospital

• Head of the “Oncospecialist” Medical Oncology Group

• Coordinator of the Tumor Board for Gynaecological Cancer at Hygeia Hospital 

Editorial Boards

• Editorial Board Member in “Journal of Balkan Union of Oncology”

• AD-HOC REVIEWER for peer-reviewed international journals: “Annals of Oncology”, “Br J Surg”, “AJPP”

• External Reviewer of «Vulvar Cancer Guidelines». European Society of Gynae-cological Oncology (ESGO)


Work Experience

• 01.02.2016 – today Medical Oncologist YGEIA & MITERA Hospital

• 30.01.2014 – 30.01.2016 Consultant Medical Oncologist, 2nd Department of Medical Oncology, “Saint Savvas” Cancer Hospital, Athens, Greece

• 08.07.2013 – 08.01.2014 Clinical Research Fellow in Gynae/Oncology, The Royal Marsden NHS Foundation Trust, London, United Kingdom

• 29.03.2013 – 29.05.2013 Medical Oncologist, 1st Department of Medical Oncology, Metaxa Cancer Hospital, Piraeus, Greece

• 29.03.2009 – 29.03.2013 Resident Doctor in Medical Oncology, 1st Department of Medical Oncology, Metaxa Cancer Hospital, Piraeus, Greece

• 06.2008-12.2008 Resident Doctor in Hematology, Department of Pathophysiology, Medical School, University of Athens, Greece

• 06.2006-06.2008 Resident Doctor in Internal Medicine, 1st Department of Internal Medicine, Asclepeion General Hospital, Athens, Greece

• 12.2005-03.2010 Research associate Doctor in Medical Oncology, Department of Pathophysiology, Medical School, University of Athens, Greece

• 12.2004-08.2005 Compulsory military service as a Sergeant Doctor, Hellenic Army, Air Force

• 08.2003-08.2004 Rural Doctor at the Health Center of Dimitsana, Arkadia, Greece 

• 05.2004-08.2004 Rural Doctor at the General Regional Hospital of Tripolis, Greece

Education Experience

• Tutor in the Hellenic Boards of Oncology 2014, 2023

• Tutor in the Post Graduate program in Clinical Pharmacology of the Pharmacology School – University of Athens. Subject: Pathophysiolo-gy and treatment of ovarian and uterine cancer. 2021, 2022

• Professor of Medical Anatomy and Physiology in Medical Imaging Devices Faculty, Public Institute of Professional Training, Markopoulo, Attiki, Greece 2005–2006


Clinical & Research Interest

• Special interest in gynaecological cancer. Medical Oncology – Researcher and member of the  European Network for Gynaecological Oncological Trial groups (ENGOT) and member of the Gynaecological Cancer Academy.

• Member of the European experts consensus panel for gynaecological oncology guidelines.

• Principal investigator in several clinical trials  (pes Principal Investigator in RUBY, ENGOT-cx11-Α18, XPORT, GLORIOSA, LAVENDER and SI in ICON8 CCR3622, PETROC CCR3538, OSI-906 CCR3266, AZD2281 V PLACEBO CCR3209, ICON6 CCR3026, TRINOVA-2 CCR3633, 6MP CCR3632, BASKET CCR3775, PARAGON CCR3783, MK1775 CCR3680, ENDOCYTE/PROCEED CCR 3917, DESKTOP CCR3803, SYMPTOM BENEFIT STUDY CCR3912, SOLO-1 CCR4043). 

• Participation and presentation of Published articles, Reviews, Current Advacnes in the Gynaecological Cancer field in National and International Boards, Seminars, Masterclasses and Congresses. 

• Ranked in global expert opinion leader lists for Gynaecological Cancer. 

Honors & Awards

•  Prize for the best oral presentation “Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study” 7th Congress of Balkan Union of Oncology, Kusadasi, Turkey, 15-19 October 2008

•  Scholarship granted by the Hellenic Society of Medical Oncology (HeSMO), 2013 

•  Scholarship granted by the European School of Oncology (ESO), 2013


• “Gastric Cancer: From Staging to Surgical Treatment. Procedures, Complications and Oncological Results” NOVA publishers ISBN: 978-1-62081-294-5 Chapter 3: Surgical Treatment of Early and Advanced Disease and Prognostic Factors

• ¨CRITICAL CARE AND EMERGENCY MEDICINE: MONITORING¨ Pashalidis Editions, Athens 2009 Lung Cancer Monitoring Chapter

Recent Publications

• Testing of newly diagnosed advanced high grade ovarian cancer (OC) patients with the Myriad Genetics MyChoice CDx Plus next generation sequencing-based in vitro diagnostic test emphasizes the need for public insurance coverage of genetic testing: Results of a national program by the Hellenic Society of Medical Oncology (HeSMO). ASCO 2022 Annual Meeting. J Clin Oncol 40, 2022 (suppl 16; abstr e18520). DOI 10.1200/JCO.2022.40.16_suppl.e18520

• European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer. I Vergote et European experts’ consensus group. Ann Oncol. 2021 Dec 1;S0923-7534(21)04828-6. doi: 10.1016/j.annonc.2021.11.013.

• Combination of weekly topotecan and gemcitabine as a salvage treatment in patients with recurrent ovarian cancer: a phase I study. Minerva Ginecol. 2019 Feb 6. 

• Real-World Data on Health-Related Quality of Life Assessment in Patients With Breast Cancer Receiving Subcutaneous Trastuzumab. Breast Cancer (Auckl). 2018 Feb 20;12:1178223418758031. 

• Mucinous cystadenocarcinoma of the breast: the challenge of diagnosing a rare entity. Rare Tumors. 2017 Oct 3;9(3):7016. 

• An ovarian mature cystic teratoma evolving in squamous cell carcinoma: A case report and review of the literature. Gynecol Oncol Rep. 2016 Dec 18;19:27-30. 

• Distinct patterns of angiogenic factor expression as a predictive factor of response to chemotherapy in stage IIIA non‑small‑cell lung cancer patients. Mol Clin Oncol. 2016 Oct;5(4):440-446. 

• Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer. Expert Rev Anticancer Ther. 2015 Aug;15(8):875-84. 

• Advances in thymic carcinoma diagnosis and treatment: a review of literature. Med Oncol. 2014 Jul;31(7):44. PMID: 24906655. Syrios J, Diamantis N, Fergadis E, et al.

• Advanced Epithelial Ovarian Cancer: From Standard Chemotherapy to Promising Molecular Pathway Targets – Where Are we Now? Anticancer Res. 2014 May;34(5):2069-77. PMID: 24778008.